SLC5A2 and plasma cell myeloma: A small retrospective study of diabetics with multiple myeloma at a single center found that there was a 42.4% rate of SGLT2 inhibitor discontinuation, with 21.4% attributed to worsening renal function, but no evidence of increased risk of infection.14